Prosecution Insights
Prosecution Insights
4 pending office actions • 2 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| No statute on record | 3 (75%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BURKETT, DANIEL JOHN | 2 | 65.4% | +24.5% |
| KUCKLA, ANNA GRACE | 1 | 51.3% | +52.1% |
| ANDERSON, REBECCA L | 1 | 73.2% | +24.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18256091 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | BURKETT, DANIEL JOHN | 131d overdue |
| 18027313 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BURKETT, DANIEL JOHN | 46d overdue |
| 18572412 | SHP2 AND CDK4/6 INHIBITORS COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | KUCKLA, ANNA GRACE | 19d overdue |
| 18572399 | ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY | ANDERSON, REBECCA L | 4d overdue |
| Art Unit | Apps |
|---|---|
| 1626 | 2 |
| 1624 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18572412 | SHP2 AND CDK4/6 INHIBITORS COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | KUCKLA, ANNA GRACE | 1626 | Other | Non-Final OA | 19d overdue | Pending | Dec 20, 2023 |
| 18572399 | ERK1/2 AND KRAS G12C INHIBITORS COMBINATION THERAPY | ANDERSON, REBECCA L | 1626 | §103 | Non-Final OA | 4d overdue | Pending | Dec 20, 2023 |
| 18256091 | COMBINATION THERAPIES FOR THE TREATMENT OF CANCER | BURKETT, DANIEL JOHN | 1624 | Other | Non-Final OA | 131d overdue | Pending | Jun 06, 2023 |
| 18027313 | COMPOSITIONS AND METHODS FOR TREATING CANCER | BURKETT, DANIEL JOHN | 1624 | Other | Final Rejection | 46d overdue | Pending | Mar 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial